Inflammatory mechanisms and oxidative stress in Peyronie's disease: Therapeutic "rationale" and related emerging treatment strategies

Inflammation and Allergy - Drug Targets

Volumn 11, Issue 1, 2012, Pages 48-57

  Paulis, Gianni ^a   Brancato, Tommaso ^a  

^a REGINA APOSTOLORUM HOSPITAL   (Italy)

Author keywords

Free radicals; Nitrosative stress; Oxidative stress; Peyronie's disease; Peyronie's disease treatment; Radical oxygen species

Indexed keywords

4 AMINOBENZOATE POTASSIUM; ALPHA TOCOPHEROL; ALPHA2A INTERFERON; BETA INTERFERON; CALCIUM CHANNEL BLOCKING AGENT; COLCHICINE; COLLAGENASE; DICLOFENAC; FIBROBLAST GROWTH FACTOR; FLAVONOID; HYALURONIDASE; HYDROGEN PEROXIDE; HYDROPEROXIDE; HYDROXYL RADICAL; I KAPPA B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON; INTERLEUKIN 1; LEVACECARNINE; PENTOXIFYLLINE; PEROXYNITRITE; PLATELET DERIVED GROWTH FACTOR; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; SUPEROXIDE DISMUTASE; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VERAPAMIL;

ARTICLE; BONE DEVELOPMENT; BREAST CARCINOMA; DNA FRAGMENTATION; DNA TRANSCRIPTION; DRUG MEGADOSE; FEVER; FIBROBLAST; GOUT; HUMAN; IN VITRO STUDY; INFLUENZA; NEUTROPHIL; OXIDATIVE STRESS; PENIS INJURY; PEYRONIE DISEASE; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; TUNICA ALBUGINEA;

EID: 84855822397     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152812798889321     Document Type: Article

References (125)

1. Brock, G.; Hsu, G.L.; Nunes, L.; von Heyden, B.; Lue TF. The anatomy of the tunica albuginea in the normal penis and Peyronie's disease. J. Urol., 1997, 157(1), 276-281.
2. De La Peyronie, F. Sur quelques obstacles qui sópposent à l'éjaculation naturelle de la semence. Mem. Acad Royale Chir., 1743, 1, 337-342.
3. Schiavino, D.; Sasso, F.; Nucera, E.; Alcini, E.; Gulino, G.; Milani, A.; Patriarca, G. Immunologic findings in Peyronie's disease: a controlled study. Urology, 1997, 50(5), 764-768.
4. Nachtsheim, D.A.; Rearden, A. Peyronie's disease is associated with an HLA class II antigen, HLA-DQ5, implying an autoimmune etiology. J. Uro. l, 1996, 156(4), 1330-1334.
5. Chilton, C.P.; Castle, W.M.; Westwood, C.A.; Pryor, J.P. Factors associated in the aetiology of peyronie's disease. Br. J. Urol., 1982, 54(6), 748-750.
6. Nugteren, H.M.; Nijman, J.M.; de Jong, I.J.; van Driel, M.F. The association between Peyronie's and Dupuytren's disease. Int. J. Impot. Res., 2011, 23(4), 142-145.
7. Vanni, A.J.; Bennett, N.E. Current treatment and management of the acute phase of Peyronies's disease. Arch. Esp. Urol., 2009, 62(8), 614-622.
8. Ralph, D.J.; Schwartz, G.; Moore, W.; Pryor, J.P.; Ebringer, A.; Bottazzo, G.F. The genetic and bacteriological aspects of Peyronie's disease. J. Urol., 1997,157(1), 291-294.
9. Nale, D.; Mićić, S.; Vuković, I.; Radosavljević, R. Induratio penis plastica--localized or diffusive fibromatosis of tunica albuginea penis? Vojnosanit Pregl., 2006, 63(11), 939-944.
10. Costa, WS.; Rebello, SB.; Cardoso, L.E.; Cavalcanti, A.G.; Sampaio, F.J. Stereological and biochemical analysis of muscular and connective tissue components in the penile corpus cavernosum adjacent to the fibrous plaque of Peyronie's disease. BJU Int., 2009, 103(2), 212-216.
11. Rhoden, E.L.; Riedner, C.E.; Fuchs, S.C.; Ribeiro, E.P.; Halmenschlager, G. A cross-sectional study for the analysis of clinical, sexual and laboratory conditions associated to Peyronie's disease. J. Sex. Med., 2010, 7(4 Pt 1), 1529-1537.
12. Schwarzer, U.; Sommer, F.; Klotz, T.; Braun, M.; Reifenrath, B.; Engelmann, U. The prevalence of Peyronie's disease: results of a large survey. BJU Int., 2001, 88(7), 727-730.
13. La Pera, G.; Pescatori, E.S.; Calabrese, M.; Boffini, A.; Colombo, F.; Andriani, E.; Natali, A.; Vaggi, L.; Catuogno, C.; Giustini, M.; Taggi, F.; SIMONA Study Group. Peyronie's disease: prevalence and association with cigarette smoking. A multicenter populationbased study in men aged 50-69 years. Eur. Urol., 2001, 40(5), 525-530.
14. Mulhall, J.P.; Creech, S.D.; Boorjian, S.A.; Ghaly, S.; Kim, E.D.; Moty, A.; Davis, R.; Hellstrom, W. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J. Urol., 2004, 171(6 pt 1), 2350-2353.
15. Alberg, A. The influence of cigarette smoking on circulating concentrations of antioxidant micronutrients. Toxicology, 2002, 180(2), 121-137.
16. Dietrich, M.; Block, G.; Norkus, EP.; Hudes, M.; Traber, M.G.; Cross, C.E.; Packer, L. Smoking and exposure to environmental tobacco smoke decrease some plasma antioxidants and increase gamma-tocopherol in vivo, after adjustment for dietary antioxidant intakes. Am. J. Clin. Nutr., 2003, 77(1), 160-166.
17. Mezzetti. A.; Lapenna, D.; Pierdomenico, S.D.; Calafiore, A.M.; Costantini, F.; Riario-Sforza, G.; Imbastaro, T.; Neri, M.; Cuccurullo, F. Vitamins E, C and lipid peroxidation in plasma and arterial tissue of smokers and nonsmokers. Atherosclerosis, 1995, 112(1), 91-99.
18. Stryker, W.S.; Kaplan, L.A.; Stein, E.A.; Stampfer, M.J.; Sober, A.; Willett, W.C. The relation of diet, cigarette smoking, and alcohol consumption to plasma beta-carotene and alpha-tocopherol levels. Am. J. Epidemiol., 1988, 127(2), 283-296.
19. Devine, C.J. Jr.; Somers, K.D.; Jordan, G.H.; Schlossberg, S.M. Proposal: trauma as the cause of the Peyronie's lesion. J. Urol., 1997, 157(1), 285-290.
20. Jarow, J.P.; Lowe, F.C. Penile trauma: an etiologic factor in Peyronie's disease and erectile dysfunction. J. Urol., 1997, 158(4), 1388-1390.
21. Zargooshi, J. Trauma as the cause of Peyronie's disease: penile fracture as a model of trauma. J. Urol., 2004, 172(1), 186-188.
22. Zargooshi, J. Sexual function and tunica albuginea wound healing following penile fracture: An 18-year follow-up study of 352 patients from Kermanshah, Iran. J. Sex Med., 2009, 6(4), 1141-1150.
23. Williams, J.L.; Thomas, G.G. The natural history of Peyronie's disease. J. Urol., 1970, 103(1), 75-76.
24. Gelbard, M.K.; Dorey, F.; James, K. The natural history of Peyronie's disease. J. Urol., 1990, 144(6), 1376-1379.
25. Kadioglu, A.; Tefekli, A.; Erol, B.; Oktar, T.; Tunc, M.; Tellaloglu, S. A retrospective review of 307 men with Peyronie's disease; results of a large survey. BJU Int., 2001, 88(7), 727-730.
26. Mulhall, J.P.; Schiff, J.; Guhring, P. An analysis of the natural history of Peyronie's disease. J. Urol., 2006, 175(6), 2115-2118.
27. Riedl, C.R.; Plas, E.; Engelhardt, P.; Daha, K.; Pflüger, H. Iontophoresis for treatment of Peyronie's disease. J. Urol., 2000, 163(1), 95-99.
28. Hauck, E.W.; Diemer, T.; Schmelz, H.U.; Weidner, W. A Critical Analysis of Nonsurgical treatment of Peyronie's disease. Eur. Urol., 2006, 49(6), 987-997.
29. Trost, L.W.; Gur, S.; Hellstrom, W.J. Pharmacological Management of Peyronie's Disease. Drugs, 2007, 67(4), 527-545.
30. Taylor, F.L.; Levine, L.A. Non-surgical therapy of Peyronie's disease. Asian J. Androl., 2008, 10(1), 79-87.
31. Gontero, P.; Di Marco, M.; Giubilei, G.; Bartoletti, R.; Pappagallo, G.; Tizzani, A.; Mondaini N. Use of penile extender device in the treatment of penile curvature as a result of Peyronie's disease. Results of a phase II prospective study. J. Sex Med., 2009, 6(2), 558-566.
32. Diegelmann, R.F. Cellular and biochemical aspects of normal and abnormal wound healing: an overview. J. Urol., 1997, 157(1), 298-302.
33. Somers, K.D.; Dawson, D.M. Fibrin deposition in Peyronie's disease plaque. J. Urol., 1997, 157(1), 311-315.
34. Van de Water, L. Mechanisms by which fibrin and fibronectin appear in healing wounds: implications for Peyronie's disease. J. Urol., 1997, 157(1), 306-310.
35. Moreland, R.B.; Nehra, A. Pathophysiology of Peyronie's disease. Int. J. Impot. Res., 2002, 14(5), 406-410.
36. Gentile. V.; Modesti, A.; La Pera, G.; Vasaturo, F.; Modica, A.; Prigiotti, G.; Di Silverio, F.; Scarpa, S. Ultrastructural and immunohistochemical characterization of the tunica albuginea in Peyronie's disease and veno-occlusive function. J. Androl., 1996, 17(2), 96-103.
37. El-Sakka, A.I.; Hassoba, H.M.; Chui, R.M.; Bhatnagar, R.S.; Dahiya, R.; Lue, T.F. An animal model of Peyronie's-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J. Urol., 1997, 158(6), 2284-2290.
38. Zimmermann, R.P.; Feil, G.; Bock, C.; Hoeltl, L.; Stenzl, A. Significant alterations of serum cytokine levels in patients with Peyronie's disease. Int. Braz J. Urol., 2008, 34(4), 457-466; discussion 466.
39. Li, Y.; Foster, W.; Deasy, B.M.; Chan, Y.; Prisk, V.; Tang, Y.; Cummins, J.; Huard, J. Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. Am. J. Pathol., 2004, 164(3), 1007-1019.
40. Vernet, D.; Nolazco, G.; Cantini, L.; Magee, T.R.; Qian, A.; Rajfer, J.; Gonzalez-Cadavid, N.F. Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: implications for peyronie disease. Biol. Reprod., 2005, 73(6), 1199-1210.
41. Cantini, L.P.; Ferrini, M.G.; Vernet, D.; Magee, T.R.; Qian, A.; Gelfand, R.A.; Rajfer, J.; Gonzalez-Cadavid, N.F. Profibrotic role of myostatin in Peyronie's disease. J. Sex Med., 2008, 5(7), 1607-1622.
42. Ross R, Raines EW, Bowen-Pope DF. The biology of plateletderived growth factor. Cell, 1986, 46(2), 155-169.
43. Bivalacqua, T.J.; Champion, H.C.; Hellstrom, W.J. Implications of nitric oxide synthase isoforms in the pathophysiology of Peyronie's disease. Int. J. Impot. Res., 2002, 14(5), 345-352.
44. Mulhall, J.P.; Thom, J.; Lubrano, T.; Shankey, T.V. Basic fibroblast growth factor expression in Peyronie's disease. J. Urol., 2001, 165(2), 419-423.
45. Davila, H.H.; Magee, T.R.; Zuniga, F.I.; Rajfer, J.; Gonzalez-Cadavid, N.F. Peyronie's disease associated with increase in plasminogen activator inhibitor in fibrotic plaque. Urology, 2005, 65(4), 645-648.
46. Luangkhot, R.; Rutchik, S.; Agarwal, V.; Puglia, K.; Bhargava, G.; Melman, A. Collagen alterations in the corpus cavernosum of men with sexual dysfunction. J. Urol., 1992, 148(2 Pt 1), 467-471.
47. Somers, K.D.; Sismour, E.N.; Wright, G.L. Jr.; Devine, C.J. Jr.; Gilbert, D.A.; Horton, C.E. Isolation and characterization of collagen in Peyronie's disease. J. Urol., 1989, 141(3), 629-631.
48. Gonzalez-Cadavid, N.F.; Rajfer, J. Molecular and cellular aspects of the pathophysiology of Peyronie's disease. Drug Discov. Today Dis. Mech., 2004, 1, 99-104.
49. Vernet, D.; Nolazco, G.; Cantini, L.; Magee, T.R.; Qian, A.; Rajfer, J.; Gonzalez-Cadavid N.F. Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: implications for peyronie disease. Biol. Reprod., 2005, 73(6), 1199-1210.
50. Gonzalez-Cadavid, N.F.; Magee, T.R.; Ferrini, M.; Qian, A.; Vernet, D.; Rajfer, J. Gene expression in Peyronie's disease. Int. J. Impot. Res., 2002, 14(5), 361-374.
51. Ferrini, M.G.; Vernet, D.; Magee, T.R.; Shahed, A.; Qian, A.; Rajfer, J.; Gonzalez-Cadavid, N.F. Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide, 2002, 6(3), 283-294.
52. Rajasekaran, M.; Hellstrom, W.J.; Sikka, S.C. Nitric oxide induces oxidative stress and mediates cytotoxicity to human cavernosal cells in culture. J. Androl., 2001, 22(1), 34-39.
53. Sikka, S.C.; Hellstrom, W.J.G. Role of oxidative stress and antioxidants in Peyronie's disease. Int. J. Impot. Res., 2002, 14(5), 353-360.
54. Taylor, F.L.; Levine, L.A. Non-surgical therapy of Peyronie's disease. Asian J. Androl., 2008, 10(1), 79-87.
55. Levine, L.A.; Merrick, P.F.; Lee, R.C. Intralesional verapamil injection for the treatment of Peyronie's disease. J. Urol., 1994, 151(6), 1522-1524.
56. Rehman, J.; Benet, A.; Melman, A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology, 1998, 51(4), 620-626.
57. Paulis, G.; D'Ascenzo, R.; Nupieri, P.; De Giorgio, G.; Orsolini, G.; Brancato, T.; Alvaro, R. Effectiveness of antioxidants (propolis, blueberry, vitamin E) associated with verapamil in the medical management of Peyronie's disease: a study of 151 cases. Int. J. Androl., 2011, doi: 10.1111/j.1365-2605.2011.01219.x. [Epub ahead of print].
58. Arena, F.; Peracchia, G.; Di Stefano, C.; Passari, A.; Larosa, M.; Cortellini, P. Clinical effects of verapamil in the treatment of Peyronie's disease. Acta Biomed. Ateneo. Parmense, 1995, 66(6), 269-272.
59. Nicolai, M.; Cipollone, G.; Iantorno, R.; Mastroprimiano, A.Z.; Tenaglia, R. Intralesional verapamil injection versus placebo in Peyronie's disease. J. Urol., 1998, 159, 117 (abstract no. 450).
60. Zarafonetis, C.J.; Horrax, T.M. Treatment of Peyronie's disease with potassium para-aminobenzoate (potaba). J. Urol., 1959, 81(6), 770-772.
61. Weidner, W.; Hauck, E.W.; Schnitker, J.; Peyronie's Disease Study Group of Andrological Group of German Urologists. Peyronie's Disease Study Group of Andrological Group of German Urologists. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur. Urol., 2005, 47(4), 530-5; discussion 535-6.
62. Taylor, F.L.; Levine, L.A. Non-surgical therapy of Peyronie's disease. Asian J Androl., 2008, 10(1), 79-87.
63. Roy, J.; Carrier, S. Acute hepatitis associated with treatment of Peyronie's disease with potassium para-aminobenzoate (Potaba). J. Sex Med., 2008, 5(12), 2967-2969.
64. Mesnil, A.; Lewden, B.; Dumortier, J.; Cuche, M.; Euvrard, P.; Dorez, D.; Vial, T. Liver injury due to potassium paraaminobenzoate (Potaba). Gastroenterol. Clin. Biol., 2004, 28(12), 1295-1296.
65. Safarinejad, M.R. Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study. Int J Impot Res., 2004, 16(3), 238-243.
66. Hellstrom, W.J.; Kendirci, M.; Matern, R.; Cockerham, Y.; Myers, L.; Sikka, S.C.; Venable, D.; Honig, S.; McCullough, A.; Hakim, L.S.; Nehra, A.; Templeton, L.E.; Pryor, J.L. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J. Urol., 2006, 176(1), 394-398.
67. Judge, J.S.; Wisniewski, Z.S. Intralesional interferon in the treatment of Peyronie's disease: a pilot study. Br. J. Urol., 1997, 79: 40-42.
68. Polat, O.; Gül, O.; Ozbey, I.; Ozdikici, M.; Bayraktar, Y. Peyronie's disease: intralesional treatment with interferon alpha-2A and evaluation of the results by magnetic resonance imaging. Int. Urol. Nephrol., 1997, 29(4), 465-471.
69. Teloken, C.; Rhoden, E.L.; Grazziotin, T.M.; Ros, C.T.; Sogari, P.R.; Souto, C.A. Tamoxifen versus placebo in the treatment of Peyronie's disease. J. Urol., 1999, 162(6), 2003-2005.
70. Gelbard, M.K.; James, K.; Riach, P.; Dorey, F. Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study. J. Urol., 1993, 149(1), 56-58.
71. Glina, S.; Gelbard, M.K.; Akkus, E.; Jordan, G.H.; Levine, L.A. The use of collagenase in the treatment of Peyronie's disease M.K. Gelbard, A. Lindner, and J.J. Kaufman. J. Sex Med., 2007, 4(5), 1209-1213.
72. Jordan, G.H. The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, singlecenter, non-placebo-controlled study. J. Sex Med., 2008, 5(1), 180-187.
73. Del Carlo, M.; Cole, A.A.; Hart, S.G.E.; Levine, L.A. Comparative analysis of collagen degradation in Peyronie's disease plaque and Dupuytren's contracture cord tissues injected with mixed collagenase subtypes. J. Urol., 2009, 181(4 Suppl 1):S279-279.
74. Jang. Q.; Yin, X.; Lill, M.A.; Danielson, M.L.; Freiser, H.; Huang, J. Long-chain carboxychromanols, metabolites of vitamin E, are potent inhibitors of cyclooxygenases. Proc. Natl. Acad Sci., USA, 2008, 105(51), 20464-20469.
75. O'Leary, K.A.; de Pascual-Tereasa, S.; Needs, P.W.; Bao, Y.P.; O'Brien, NM.; Williamson, G. Effect of flavonoids and vitamin E on cyclooxygenase-2 (COX-2) transcription. Mutat. Res., 2004, 551(1-2), 245-254.
76. Pryor, J.P.; Farrell, C.F. Controlled clinical trial of vitamin E in Peyronie's disease. Prog. Reprod. Biol., 1983, 9, 41-45.
77. Hashimoto, K.; Hisasue, S.; Kato, R.; Kobayashi, K.; Shimizu, T.; Tsukamoto, T. Outcome analysis for conservative management of Peyronie's disease. Int. J. Urol., 2006, 13(3), 244-247.
78. Natarajan, K.; Singh, S.; Burke, T.R. Jr.; Grunbergerm, D.; Aggarwal, B.B. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc. Natl. Acad Sci. USA, 1996, 93(17), 9090-9095.
79. Marquez, N.; Sancho, R.; Macho, A.; Calzado, M.A.; Fiebich, B.L.; Munoz, E. Caffeic acid phenethyl ester inhibits T-cell activation by targeting both nuclear factor of activated T-cells and NF-kappaB transcription factors. J. Pharmacol. Exp. Ther., 2004, 308(3), 993-1001.
80. Song, J.J.; Cho, J.G.; Hwang, S.J.; Cho, C.G.; Park, S.W.; Chae, S.W. Inhibitory effect of caffeic acid phenethyl ester (CAPE) on LPS-induced inflammation of human middle ear epithelial cells. Acta Otolaryngol., 2008, 128(12), 1303-1307.
81. Ha, S.K.; Moon, E.; Kim, S.Y. Chrysin suppresses LPS-stimulated proinflammatory responses by blocking NF-κB and JNK activations in microglia cells. Neurosci. Lett., 2010, 485(3), 143-147.
82. Lemourt Oliva, M.; Rodriguez Barroso, A.; Puente Guillen, M.; Vega Guerrero, C.; Navarro Cutino, M.; Perez Monzon, A. Propoleum and Peyronie's disease. Arch. Esp. Urol., 2003, 56(7), 805-813.
83. Lemourt Oliva, M.; Fragas Valdes, R.; Bordonado Ramirez, R.; Santana, J.L.; Gonzalez Oramas, E.; Merino, A. Peyronie's disease. Evaluation of 3 therapeutic modalities: propoleum, laser and simultaneous propoleum-laser. Arch Esp. Urol., 2005, 58(9), 931-935.
84. Lemourt Oliva, M.; Filgueiras Lopez, E.; Rodri{dotless}guez Barroso, A.; Gonzalez Oramas, E.; Bordonado, R. Clinical evaluation of the use of propoleum in Peyronie's disease. Arch Esp. Urol., 1998, 51(2), 171-176.
85. Lemourt Oliva, M.; Rodriguez Barroso, A.; Bordonado Ramirez, R.; Gonzalez Oramas, E.; Molina Castillo, F. Study of propoleum dosage in Peyronie's disease. Arch Esp. Urol., 2003, 56(7), 814-819.
86. Shindel, AW.; Lin, G.; Ning, H.; Banie, L.; Huang, Y.C.; Liu, G.; Lin, C.S.; Lue, T.F. Pentoxifylline attenuates transforming growth factor-β1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix. J. Sex Med., 2010, 7(6), 2077-2085.
87. Deree, J.; Martins, J.O.; Melbostad, H.; Loomis, W.H.; Coimbra, R. Insights into the regulation of TNF-alpha production in human mononuclear cells: the effects of non-specific phosphodiesterase inhibition. Clinics (Sao Paulo)., 2008, 63(3), 321-328.
88. Safarinejad, M.R.; Asgari, M.A.; Hosseini, S.Y.; Dadkhah, F. A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease. BJU Int., 2010, 106(2), 240-248.
89. Calò, L.A.; Pagnin, E.; Davis, P.A.; Semplicini, A.; Nicolai, R.; Calvani, M.; Pessina, A.C. Antioxidant effect of L-carnitine and its short chain esters: relevance for the protection from oxidative stress related cardiovascular damage. Int. J. Cardiol., 2006, 107(1), 54-60.
90. Biagiotti, G.; Cavallini, G. Acetyl-L-carnitine vs, tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int., 2001, 88(1), 63-67.
91. Choi, H.K.; Pokharel, Y.R.; Lim, S.C.; Han, H.K.; Ryu, C.S.; Kim, S.K.; Kwak, M.K.; Kang, K.W. Inhibition of liver fibrosis by solubilized coenzyme Q10: Role of Nrf2 activation in inhibiting transforming growth factor-beta1 expression. Toxicol. Appl. Pharmacol., 2009, 240(3), 377-384.
92. Safarinejad, M.R. Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease: a doubleblind, placebo-controlled randomized study. Int. J. Impot. Res., 2010, 22(5), 298-309.
93. Gustafson, H.; Johansson, B.; Edsmyr, F. Peyronie's disease: experience of local treatment with Orgotein. Eur. Urol., 1981, 7(6), 346-348.
94. Primus, G. Orgotein in the treatment of plastic induration of the penis (Peyronie's disease). Int. Urol. Nephrol., 1993, 25(2), 169-172.
95. Vouldoukis, I.; Lacan, D.; Kamate, C.; Coste, P.; Calenda, A.; Mazier, D.; Conti, M.; Dugas, B. Antioxidant and antiinflammatory properties of a Cucumis melo LC. extract rich in superoxide dismutase activity. J. Ethnopharmacol., 2004, 94(1), 67-75.
96. Skarpanska-Stejnborn, A.; Pilaczynska-Szczesniak, L.; Basta, P.; Deskur-Smielecka, E.; Woitas-Slubowska, D.; Adach, Z. Effects of oral supplementation with plant superoxide dismutase extract on selected redox parameters and an inflammatory marker in a 2,000-m rowing-ergometer test. Int. J. Sport. Nutr. Exerc. Metab., 2011, 21(2), 124-134.
97. Cipollone, G.; Nicolai, M.; Mastroprimiano, G.; Iantorno, R.; Longeri, D.; Tenaglia R. Betamethasone versus placebo in Peyronie's disease. Arch Ital. Urol. Androl., 1998, 70(4), 165-168.
98. Williams, G.; Green, N.A. The non-surgical treatment of Peyronie's disease. Br. J. Urol., 1980, 52(5), 392-395.
99. Levine, L.A.; Estrada, C.R.; Shou, W.; Cole, A. Tunica albuginea tissue analysis after electromotive drug administration. J. Urol., 2003, 169(5), 1775-1778.
100. Greenfield, J.M.; Shah, S.J.; Levine, L.A. Verapamil versus saline in electromotive drug administration for Peyronie's disease: a double-blind, placebo controlled trial. J. Urol., 2007, 177(3), 972-975.
101. Montorsi, F.; Salonia, A.; Guazzoni, G.; Barbieri, L.; Colombo, R.; Brausi, M.; Scattoni, V.; Rigatti, P.; Pizzini, G. Transdermal electromotive multi-drug administration for Peyronie's disease: preliminary results. J. Androl., 2000, 21(1), 85-90.
102. Di Stasi, S.M.; Giannantoni, A.; Stephen, R.L.; Capelli, G.; Giurioli, A.; Jannini, E.A.; Vespasiani, G. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. J. Urol., 2004, 171(4), 1605-1608.
103. Riedl, C.R.; Sternig, P.; Gallé, G.; Langmann, F.; Vcelar, B.; Vorauer, K.; Wagner, A.; Katinger, H.; Pflüger, H. Liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease: a randomized placebo-controlled double-blind prospective clinical study. Eur. Urol., 2005, 48(4), 656-661.
104. Martin, D.J.; Badwan, K.; Parker, M.; Mulhall, J.P. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J. Urol., 2002, 168(6), 2483-2485.
105. Levine, L.A. Review of current nonsurgical management of Peyronie's disease. Int. J. Impot. Res., 2003, 15, (Suppl 5), S113-20.
106. Frank, I.N.; Scott, W.W. The ultrasonic treatment of Peyronie's disease. J. Urol., 1971, 106(6), 83-87.
107. W. Hauck, E.W.; Hauptmann, A.; Bschleipfer, T.; Schmelz, H.U.; Altinkilic, B.M.; Weidner, W. Questionable efficacy of extracorporeal shock wave therapy in Peyronie's disease: results of a prospective approach. J. Urol., 2004, 171(1), 296-299.
108. Strebel, R.T.; Suter, S.; Sautter, T.; Hauri, D. Extracorporeal shock wave therapy for Peyronie's disease does not correct penile deformity. Int. J. Impot. Res., 2004, 16: 448-451.
109. Hauck, E.W.; Hatzichristodoulou, G.; Lahme, S. ESWT in Peyronie's disease. In: Therapeutic energy applications in Urology. Chaussy C, Haupt G, Jocham D, Köhrmann KU, Wilbert D, editors. Georg Thieme Verlag: Stuttgart, Germany, 2005, pp.137-143.
110. Hatzichristodoulou, G.; Meisner, C.; Stenzyl, A.; Lahme, S. Efficacy of extracorporeal shock wave therapy on plaque size and sexual function in patients with Peyronie's Disease-results of a prospective, randomized, placebo-controlled study. Annual Meeting of the American Urological Association, 2007, May 19-24, 2007, Anaheim, California, USA. J. Urol., 2007, 177(4 Suppl): Abstract 747.
111. Palmieri, A.; Imbimbo, C.; Longo, N.; Fusco, F.; Verze, P.; Mangiapia, F.; Creta, M.; Mirone, V. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease. Eur. Urol., 2009, 56(2), 363-369.
112. Mulhall, J.P.; Branch, J.; Lubrano, T.; Shankey, T.V. Radiation increases fibrogenic cytokine expression by Peyronie's disease fibroblasts. J. Urol., 2003, 170(1), 281-284.
113. Scroppo, F.I.; Mancini, M.; Maggi, M,; Colpi, G. M: Can an external penis stretcher reduce Peyronie's penile curvature? Int. J. Impot. Res., 2001, 13(Suppl 4) S21.
114. Levine, L.A.; Newell, M.; Taylor, F.L. Penile traction therapy for treatment of Peyronie's disease: a single-center pilot study. J. Sex Med., 2008, 5(6): 1468-1473.
115. Gontero, P.; Di Marco, M.; Giubilei, G.; Bartoletti, R.; Pappagallo, G.; Tizzani, A.; Mondaini, N. Use of penile extender device in the treatment of penile curvature as a result of Peyronie's disease. Results of a phase II prospective study. J. Sex Med., 2009, 6(2), 558-566.
116. Karlsen, A.; Retterstøl, L.; Laake, P.; Paur, I.; Kjølsrud-Bøhn, S.; Sandvik, L.; Blomhoff, R. Anthocyanins inhibit nuclear factorkappa B activation in monocytes and reduce plasma concentrations of pro-inflammatory mediators in healthy adults. J. Nutr., 2007, 137(8), 1951-1954.
117. Wang, Q.; Xia, M.; Liu, C.; Guo, H.; Ye, Q.; Hu, Y.; Zhang, Y.; Hou, M.; Zhu, H.; Ma, J.; Ling, W. Cyanidin-3-O-beta-glucoside inhibits iNOS and COX-2 expression by inducing liver X receptor alpha activation in THP-1 macrophages. Life Sci., 2008, 83(5-6), 176-184.
118. Wang, Y.; Cao, J.; Zeng, S. Involvement of P-glycoprotein in regulating cellular levels of Ginkgo flavonols: quercetin, kaempferol, and isorhamnetin. J. Pharm. Pharmacol., 2005, 57(6): 751-758.
119. Zhao, Y.; Wang, L.; Bao, Y.; Li, C. A sensitive method for the detection and quantification of ginkgo flavonols from plasma. Rapid Commun. Mass Spectrom., 2007, 21(6), 971-981.
120. Xiao, X.; Shi, D.; Liu, L.; Wang, J.; Xie, X.; Kang, T.; Deng, W. Quercetin suppresses cyclooxygenase-2 expression and angiogenesis through inactivation of P300 signaling. PLoS One., 2011, 6(8), e22934. [Epub ahead of print].
121. Sun, B.; Sun, G.B.; Xiao, J.; Chen, R.C.; Wang, X.; Wu, Y.; Cao, L.; Yang, Z.H.; Sun, X.B. Isorhamnetin inhibits H(2) O(2)-induced activation of the intrinsic apoptotic pathway in H9c2 cardiomyocytes through scavenging reactive oxygen species and ERK inactivation. J. Cell Biochem., 2011, doi: 10.1002/jcb.23371. [Epub ahead of print]
122. Zhang, L.; Ravipati, A.S.; Koyyalamudi, S.R.; Jeong, S.C.; Reddy, N.; Smith, P.T.; Bartlett, J.; Shanmugam, K.; Münch, D.G.; Wu, M.J. Antioxidant and Anti-inflammatory Activities of Selected Medicinal Plants Containing Phenolic and Flavonoid compounds. J. Agric. Food Chem., 2011, doi: 10.1021/jf203146e [Epub ahead of print]
123. Ferrini, M.G.; Kovanecz, I.; Nolazco, G.; Rajfer, J.; Gonzalez-Cadavid, N.F. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. BJU Int., 2006, 97(3), 625-633.
124. Gonzalez-Cadavid, N.F.; Rajfer, J. Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy. Nat. Rev. Urol., 2010, 7(4), 215-221.
125. Chung, E.; Deyoung, L.; Brock, G.B. The Role of PDE5 Inhibitors in Penile Septal Scar Remodeling: Assessment of Clinical and Radiological Outcomes. J. Sex Med., 2011, 8(5), 1472-1477.